Adaptive Biotechnologies 3Q 2026: Revenue $83.9M, Net income $2.9M, EPS $0.02— 10-Q Summary

Adaptive Biotechnologies reported 3Q 2026 revenue of $83.9M, down 10.7% YoY, with net income of $2.9M and EPS of $0.02. MRD revenue grew 28% quarterly, offsetting the end of the Genentech collaboration. The company plans to separate its businesses and expects MRD revenue growth, while Immune Medicine revenue may decline.

Original reporting
Published Nov 4, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adaptive Biotechnologies 3Q 2026: Revenue $83.9M, Net income $2.9M, EPS $0.02— 10-Q Summary — source image
Decision brief

The 30-second read

$ADPTBullishMed
01

Why it matters

The earnings miss may trigger short‑term selling pressure, though the rise in MRD test volume could support future recovery.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for short‑term traders monitoring earnings surprises.

03

What to watch

Potential upside from expanded Medicare coverage for mantle cell lymphoma monitoring.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Adaptive Biotechnologies disclosed its Q3 2026 results via a 10‑Q filing, noting a decline in overall revenue due to the end of a Genentech partnership but growth in MRD testing.

Company-level read

Ticker impact

$ADPTBullishHigh confidence
Context

Adaptive Biotechnologies reported Q3 2026 revenue of $83.9M, down 10.7% YoY and net income of $2.9M, indicating a earnings miss.

Expected impact

likely downward pressure as investors price in weaker revenue and reduced guidance

Evidence & confidence

Revenue decline and lower net income are fresh disclosures that typically trigger sell‑offs in micro‑cap biotech stocks.

Market effects

Biotech sector may see modest pullback as earnings miss highlights reliance on collaborations.

US biotech investors may reassess exposure to companies with similar partnership structures.

Limited; primarily affects US-listed biotech micro‑caps.

Counterpoint

If the MRD revenue growth offsets the Genentech loss, the stock could be undervalued on a longer horizon.

Key entities

  • Adaptive Biotechnologies

    US‑listed biotech firm (ticker ADPT) reporting Q3 2026 earnings.

  • Genentech

    Former collaboration partner whose contract ended, impacting revenue.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.

$ADPTHighAI 8/10

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet